Evaluación del perfil de sensibilidad de Escherichia coli aislada de infección del tracto urinario a los antimicrobianos

Autores/as

DOI:

https://doi.org/10.33448/rsd-v10i10.18742

Palabras clave:

Antimicrobianos; Escherichia coli; Infección del tracto urinário; Prueba de sensibilidade; Resistencia.

Resumen

El agente etiológico más comúnmente aislado de las infecciones del tracto urinario (ITU) es la bacteria Escherichia coli (E. coli), que representa alrededor del 40% de los casos. Como microorganismos Gram-negativos, E. coli tiene una pared celular compleja, razón por la cual algunos antibióticos son menos efectivos en comparación con su acción contra las bacterias Gram-positivas. Por tanto, el objetivo de este trabajo es evaluar el perfil de sensibilidad de muestras clínicas de la bacteria E. coli a los antimicrobianos utilizados en el tratamiento de las ITU a través de la prueba de difusión en agar. Después de la recopilación y el análisis de los datos, fue posible observar que la mayoría de los aislados clínicos eran resistentes a la amoxicilina y más sensibles a la nitrofurantoína y al cloranfenicol. De la información obtenida luego del análisis de los datos se pudo observar que a pesar del estricto control de la administración de antimicrobianos, la incidencia de bacterias resistentes a dichos fármacos es alarmante.

Citas

Bader, M. S., Loeb, M., & Brooks, A. A. (2017). An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate Medicine, 129(2), 242–258. https://doi.org/10.1080/00325481.2017.1246055

Bail, L., Ito, C. A. S., & Esmerino, L. A. (2006). Infecção do trato urinário: comparação entre o perfil de susceptibilidade e a terapia empírica com antimicrobianos. Rbac, 38(1), 51–56.

Bono, M. J., & Reygaert, W. C. (2017). Urinary tract infection.

Bono, M. J., Reygaert, W. C., & Doerr, C. (2021). Urinary Tract Infection (Nursing).

Campana, E. H., Carvalhaes, C. G., Barbosa, P. P., De Oliveira MacHado, A. M., De Paula, A. M., & Gales, A. C. (2011). Avaliação das metodologias M.I.C.E.®, Etest® e microdiluição em caldo para determinação da CIM em isolados clínicos. Jornal Brasileiro de Patologia e Medicina Laboratorial, 47(2), 157–164. https://doi.org/10.1590/S1676-24442011000200011

Carlsen, S., Krall, S. P., Xu, K. T., Tomanec, A., Farias, D., & Richman, P. (2019). Sensitivity of urinary pathogens for patients discharged from the emergency department compared with the hospital antibiogram. BMC Emergency Medicine, 19(1), 50. https://doi.org/10.1186/s12873-019-0264-z

de Cueto, M., Aliaga, L., Alós, J.-I., Canut, A., Los-Arcos, I., Martínez, J. A., Mensa, J., Pintado, V., Rodriguez-Pardo, D., Yuste, J. R., & Pigrau, C. (2017). Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enfermedades Infecciosas y Microbiologia Clinica (English Ed.), 35(5), 314–320. https://doi.org/10.1016/j.eimce.2017.03.021

de Velde, F., de Winter, B. C. M., Koch, B. C. P., van Gelder, T., & Mouton, J. W. (2016). Non-linear absorption pharmacokinetics of amoxicillin: Consequences for dosing regimens and clinical breakpoints. Journal of Antimicrobial Chemotherapy, 71(10), 2909–2917. https://doi.org/10.1093/jac/dkw226

Erb, S., Frei, R., Tschudin Sutter, S., Egli, A., Dangel, M., Bonkat, G., & Widmer, A. F. (2018). Basic patient characteristics predict antimicrobial resistance in E. coli from urinary tract specimens: a retrospective cohort analysis of 5246 urine samples. Swiss Medical Weekly, 148(4546), w14660. https://doi.org/10.4414/smw.2018.14660

Estrada, A., Wright, D. L., & Anderson, A. C. (2016). Antibacterial antifolates: From development through resistance to the next generation. Cold Spring Harbor Perspectives in Medicine, 6(8), a028324. https://doi.org/10.1101/cshperspect.a028324

Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 13(5), 269–284. https://doi.org/10.1038/nrmicro3432

Geerlings, S. E. (2016). Clinical presentations and epidemiology of urinary tract infections. Urinary Tract Infections: Molecular Pathogenesis and Clinical Management, 4(5), 27–40. https://doi.org/10.1128/9781555817404.ch2

Hughes, D., & Andersson, D. I. (2017). Evolutionary Trajectories to Antibiotic Resistance. Annual Review of Microbiology, 71, 579–596. https://doi.org/10.1146/annurev-micro-090816-093813

Huttner, A., Verhaegh, E. M., Harbarth, S., Muller, A. E., Theuretzbacher, U., & Mouton, J. W. (2015). Nitrofurantoin revisited: A systematic review and meta-analysis of controlled trials. Journal of Antimicrobial Chemotherapy, 70(9), 2456–2464. https://doi.org/10.1093/jac/dkv147

José Barbas Rodrigues, F., & Paula Dias Barroso, A. (2011). Etiology and bacterial susceptibility to urinary tract infections. Revista Portuguesa de Saude Publica, 29(2), 123–131. https://doi.org/10.1016/S0870-9025(11)70016-5

Kaufman, J., Temple-Smith, M., & Sanci, L. (2019). Urinary tract infections in children: An overview of diagnosis and management. BMJ Paediatrics Open, 3(1). https://doi.org/10.1136/bmjpo-2019-000487

Koch, C. R., Ribeiro, J. C., Schnor, O. H., Zimmermann, B. S., Müller, F. M., D’Agostin, J., Machado, V., & Zhang, L. (2008). Resistência antimicrobiana dos uropatógenos em pacientes ambulatoriais, 2000-2004. Revista Da Sociedade Brasileira de Medicina Tropical, 41, 277–281.

Krauß, J., & Bracher, F. (2018). Pharmacokinetic enhancers (Boosters)—escort for drugs against degrading enzymes and beyond. Scientia Pharmaceutica, 86(4), 43. https://doi.org/10.3390/scipharm86040043

Leão, M. V. P., Tavares, T. A. A., Gonçalves e Silva, C. R., dos Santos, S. S. F., Junqueira, J. C., de Oliveira, L. D., & Jorge, A. O. C. (2018). Lactobacillus rhamnosus intake can prevent the development of Candidiasis. Clinical Oral Investigations, 22(7), 2511–2518. https://doi.org/10.1007/s00784-018-2347-8

Lee, D. S., Lee, S. J., Choe, H. S., & Giacobbe, D. R. (2018). Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. BioMed Research International, 2018. https://doi.org/10.1155/2018/7656752

Leimbach, A., Hacker, J., & Dobrindt, U. (2013). E. coli as an all-rounder: The thin line between commensalism and pathogenicity. Current Topics in Microbiology and Immunology, 358, 3–32. https://doi.org/10.1007/82_2012_303

Lopes, A. A., Salgado, K., Martinelli, R., & Rocha, H. (1998). Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture. Revista Da Associação Médica Brasileira (1992), 44(3), 196–200. https://doi.org/10.1590/S0104-42301998000300006

McLellan, L. K., & Hunstad, D. A. (2016). Urinary Tract Infection: Pathogenesis and Outlook. Trends in Molecular Medicine, 22(11), 946–957. https://doi.org/10.1016/j.molmed.2016.09.003

Michel, P., Pereira, B., Regina, S., & Souza, B. De. (2021). Prevalência e caracterização da infecção do trato urinário inferior em mulheres atendidas na atenção primária de saúde Prevalence and characterization of lower urinary tract infection in women met in health primary care. April, 37–42. https://doi.org/10.18378/rebes.v9i1.6170

Moura, L. B., & Fernandes, M. G. (2010). A incidência de infecções urinárias causadas por E. coli. Revista Olhar Científico–Faculdades Associadas de Ariquemes, 1(2).

Paralikar, P., Ingle, A. P., Tiwari, V., Golinska, P., Dahm, H., & Rai, M. (2019). Evaluation of antibacterial efficacy of sulfur nanoparticles alone and in combination with antibiotics against multidrug-resistant uropathogenic bacteria. Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering, 54(5), 381–390. https://doi.org/10.1080/10934529.2018.1558892

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.[e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio. ufsm. br/bitstream/handle ….

Pires, M. C. D. S., Frota, K. D. S., Martins, P. D. O., Correia, A. F., Cortez-Escalante, J. J., & Silveira, C. A. (2007). Prevalence and bacterial susceptibility of community acquired urinary tract infection in University Hospital of Brasília, 2001 to 2005. Revista Da Sociedade Brasileira de Medicina Tropical, 40(6), 643–647. https://doi.org/10.1590/s0037-86822007000600009

Squadrito, F. J., & del Portal, D. (2017). Nitrofurantoin.

Tandogdu, Z., & Wagenlehner, F. M. E. (2016). Global epidemiology of urinary tract infections. Current Opinion in Infectious Diseases, 29(1), 73–79. https://doi.org/10.1097/QCO.0000000000000228

Thabit, A. K., Crandon, J. L., & Nicolau, D. P. (2015). Antimicrobial resistance: Impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opinion on Pharmacotherapy, 16(2), 159–177. https://doi.org/10.1517/14656566.2015.993381

Wang, J. Y., Liao, L., Liu, M., Sumarsono, B., & Cong, M. (2018). Epidemiology of lower urinary tract symptoms in a cross-sectional, population-based study the status in China. Medicine (United States), 97(34). https://doi.org/10.1097/MD.0000000000011554

Publicado

08/08/2021

Cómo citar

CRUZ, L. F. da .; SOUZA, I. L. A. .; SOUZA, L. D. de; CARDOSO, N. da S.; RESENDE, C. A. A.; COELHO, G. N.; ARAÚJO, M. G. de F. Evaluación del perfil de sensibilidad de Escherichia coli aislada de infección del tracto urinario a los antimicrobianos. Research, Society and Development, [S. l.], v. 10, n. 10, p. e184101018742, 2021. DOI: 10.33448/rsd-v10i10.18742. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/18742. Acesso em: 22 nov. 2024.

Número

Sección

Ciencias de la salud